[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR057854A1 - Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida - Google Patents

Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida

Info

Publication number
AR057854A1
AR057854A1 ARP060104814A ARP060104814A AR057854A1 AR 057854 A1 AR057854 A1 AR 057854A1 AR P060104814 A ARP060104814 A AR P060104814A AR P060104814 A ARP060104814 A AR P060104814A AR 057854 A1 AR057854 A1 AR 057854A1
Authority
AR
Argentina
Prior art keywords
herceptin
hki
regimen
temsirolimus
rapamycin
Prior art date
Application number
ARP060104814A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37845244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR057854A1 publication Critical patent/AR057854A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee una combinacion de temsirolimus y herceptina en el tratamiento del cáncer. Se provee una combinacion de temsirolimus y HKI-272 (E)-N-{4-[3-cloro-4-(2-piridinilmetoxi)anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida. También se provee una combinacion de herceptina y HKI-272. Se describen regímenes y kits para el tratamiento el cáncer de mama metastásico, que contienen herceptina, temsirolimus y/o HKI-272, en forma opcional en combinacion con otros agentes antineoplásicos o inmunomoduladores. Reivindicacion 1: Uso de una rapamicina en la preparacion de un medicamento antineoplásico que puede administrarse en un régimen con una herceptina, o uso de una herceptina en la preparacion de un medicamento que puede administrarse en un régimen con una rapamicina, donde dicho régimen puede en forma opcional comprender además un HKI-272. Reivindicacion 20: Una composicion farmacéutica util en el tratamiento de un neoplasma en un mamífero, la composicion que comprende: (a) al menos una unidad de temsirolimus y (b) al menos una unidad de una herceptina en forma de dosificacion unitaria y al menos un vehículo aceptable para uso farmacéutico. Reivindicacion 23: Uso de una rapamicina en la preparacion de un medicamento antineoplásico que puede administrarse en un régimen con una herceptina o uso de una herceptina en la preparacion de un medicamento que puede administrarse en un régimen con una rapamicina, donde dicho régimen de modo opcional además comprende un compuesto que presenta la formula (1) donde R1 es halogeno; R2 es piridinilo, tiofeno, pirimidina, tiazol o fenilo sustituido en forma opcional con hasta tres sustituyentes; R3 es -O- o -S-; R4 es metilo o CH2CH2OCH3; R5 es etilo o metilo; y n es 0 o 1, o una sal aceptable para uso farmacéutico del mismo.
ARP060104814A 2005-11-04 2006-11-02 Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida AR057854A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73356205P 2005-11-04 2005-11-04
US83750906P 2006-08-14 2006-08-14

Publications (1)

Publication Number Publication Date
AR057854A1 true AR057854A1 (es) 2007-12-19

Family

ID=37845244

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104814A AR057854A1 (es) 2005-11-04 2006-11-02 Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida

Country Status (17)

Country Link
US (6) US20070104721A1 (es)
EP (2) EP1942937A1 (es)
JP (7) JP2009514870A (es)
KR (1) KR101354828B1 (es)
CN (1) CN103110948A (es)
AR (1) AR057854A1 (es)
AU (1) AU2006311877A1 (es)
BR (1) BRPI0618042A2 (es)
CA (1) CA2626326C (es)
CR (1) CR9901A (es)
EC (1) ECSP088423A (es)
IL (1) IL190805A (es)
NO (1) NO20081837L (es)
PE (1) PE20070763A1 (es)
RU (2) RU2451524C2 (es)
TW (1) TW200803892A (es)
WO (1) WO2007056118A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE504299T1 (de) 2005-02-03 2011-04-15 Gen Hospital Corp Verfahren zur behandlung von gefitinib- resistentem krebs
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
CN103110948A (zh) * 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
WO2007124252A2 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009054001A1 (en) * 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
RU2010151602A (ru) * 2008-05-16 2012-06-27 Фарма Мар, С.А. (Es) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
EP3135285B1 (en) * 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP4424375A2 (en) * 2008-08-04 2024-09-04 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
PL3000467T3 (pl) * 2009-04-06 2023-05-02 Wyeth Llc Schemat leczenia wykorzystujący neratynib dla raka sutka
EP2416792A4 (en) 2009-04-10 2012-10-24 Haiyan Qi NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
NZ619375A (en) 2009-04-28 2015-03-27 Proteus Digital Health Inc Highly reliable ingestible event markers and methods for using the same
CA2780332C (en) * 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CA2783743C (en) 2009-12-11 2022-10-04 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
EP2555737A4 (en) 2010-04-07 2013-09-18 Proteus Digital Health Inc FORMABLE MINIATURE DEVICE
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2014120669A1 (en) 2013-01-29 2014-08-07 Proteus Digital Health, Inc. Highly-swellable polymeric films and compositions comprising the same
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
TWI482782B (zh) 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20180057603A1 (en) * 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
SI3033086T1 (sl) * 2013-08-14 2022-01-31 Novartis Ag Kombinirana terapija za zdravljenje raka
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
CN111772582A (zh) 2016-07-22 2020-10-16 普罗秋斯数字健康公司 可摄入事件标记的电磁感测和检测
WO2018081337A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
US20190358212A1 (en) * 2017-01-22 2019-11-28 Jiangsu Hengrui Medicine Co., Ltd. Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drug
RU2648642C1 (ru) * 2017-06-06 2018-03-26 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ неоадъювантного лечения больных местно-распространенным раком шейки матки
JP7317343B2 (ja) * 2019-03-20 2023-07-31 公立大学法人大阪 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
GB202111193D0 (en) 2021-08-03 2021-09-15 Phoremost Ltd Pharmaceutical compounds

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (es) 1992-12-18 1995-08-21 Hoffmann La Roche
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
ZA956029B (en) 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3437685B2 (ja) 1995-09-12 2003-08-18 株式会社東芝 交直変換装置の制御保護システム
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6426383B1 (en) 1997-05-28 2002-07-30 Nalco Chemical Company Preparation of water soluble polymer dispersions from vinylamide monomers
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
NZ510551A (en) 1998-09-29 2003-03-28 American Cyanamid Co Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
DE60106281T2 (de) * 2000-08-11 2005-02-24 Wyeth Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CN1309421C (zh) * 2001-04-06 2007-04-11 惠氏公司 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
BR0209647A (pt) * 2001-05-16 2004-07-27 Novartis Ag Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
US20020198137A1 (en) 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
AU2002345670A1 (en) 2001-06-14 2003-01-02 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
HUP0402228A2 (hu) 2001-11-27 2005-02-28 Wyeth Holdings Corporation EGF-R és HER2 kináz inhibitor hatású szubsztituált 3-cianokinolinok, előállításukra szolgáló eljárás, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
IL162734A0 (en) * 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
CA2487983A1 (en) 2002-06-05 2003-12-18 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
PT1553940E (pt) 2002-07-30 2008-05-09 Wyeth Corp Formulações parentéricas contendo um hidroxi-éster de rapamicina
KR20050084559A (ko) 2002-09-17 2005-08-26 와이어쓰 경구 제형
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
CN1437942A (zh) 2003-02-08 2003-08-27 杭州华卫制药技术开发有限公司 注射用长春瑞滨粉针剂及制备方法
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
ME00294B (me) 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
CN1832757A (zh) 2003-08-01 2006-09-13 惠氏控股公司 表皮生长因子受体激酶抑制剂与细胞毒性剂组合在治疗和抑制癌症中的用途
AU2004265267A1 (en) 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of CCI-779
BRPI0413667A (pt) 2003-08-19 2006-10-24 Wyeth Corp Processo para a preparação de 4-amino-3-carbonitrilas de quinolina
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1670473A1 (en) 2003-09-15 2006-06-21 Wyeth a Corporation of the State of Delaware Substituted quinolines as protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
WO2005044091A2 (en) 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7235564B2 (en) 2003-12-04 2007-06-26 Amr Technology, Inc. Vinorelbine derivatives
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
WO2005094357A2 (en) 2004-03-31 2005-10-13 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
AU2005263972A1 (en) 2004-07-23 2006-01-26 Astrazeneca Ab Method of predicting the responsiveness of a tumor to erbB receptor drugs
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
WO2006044453A1 (en) * 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
US20060084666A1 (en) 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
WO2006085168A2 (en) 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
ATE504299T1 (de) 2005-02-03 2011-04-15 Gen Hospital Corp Verfahren zur behandlung von gefitinib- resistentem krebs
WO2006081985A1 (en) 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
KR20070108270A (ko) 2005-02-28 2007-11-08 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 신규 병용
CA2610343A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Release-control composition
JP5336174B2 (ja) 2005-03-09 2013-11-06 アボット・ラボラトリーズ トラスツズマブによる治療の候補患者を確認するための診断方法
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
MX2007012662A (es) 2005-04-14 2008-04-04 Wyeth Corp Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib.
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
JP5149159B2 (ja) 2005-04-28 2013-02-20 ワイス・エルエルシー ミクロ化タナプロゲット、組成物およびその調製方法
RU2007141654A (ru) 2005-05-12 2009-05-20 Пфайзер Инк. (US) Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
BRPI0610144A2 (pt) 2005-05-25 2010-06-01 Wyeth Corp método de preparar um 3-cianoquinolina substituìda; composto representado pela fórmula i; e composto, representado pela fórmula ii
JP2008545688A (ja) 2005-05-25 2008-12-18 ワイス 置換３−シアノキノリン並びにその中間体を合成する方法
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
CN101247791A (zh) 2005-07-15 2008-08-20 惠氏公司 O-去甲基文拉法辛琥珀酸盐的高生物可利用的口服缓释剂型
JP5066446B2 (ja) 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007039705A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
WO2007050495A2 (en) 2005-10-26 2007-05-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
AR058505A1 (es) 2005-11-04 2008-02-06 Wyeth Corp Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
DK1951274T3 (da) 2005-11-24 2010-02-01 Aicuris Gmbh & Co Kg Parapoxvirusser i kombination med klasssiske cytotoksiske kemoterapeutiske midler som biokemoterapi til behandling af cancer
JP2007145745A (ja) 2005-11-25 2007-06-14 Osaka Univ 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
KR20080080205A (ko) 2005-12-22 2008-09-02 와이어쓰 티게사이클린을 포함하는 경구 제형
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
WO2007116025A2 (en) 2006-04-07 2007-10-18 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
CA2651995C (en) 2006-05-18 2017-04-25 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
EP2032989B2 (en) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2 biomarker
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
EP2077819A4 (en) 2006-09-28 2011-05-25 Follica Inc METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
US20090317456A1 (en) 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
EP2121018A2 (en) 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
NZ578329A (en) 2006-12-13 2012-05-25 Schering Corp Igf1r inhibitors for treating cancer
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
US8247421B2 (en) 2006-12-21 2012-08-21 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
EP2124901B1 (en) 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP1978106A1 (en) 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
EP2145188A4 (en) 2007-04-19 2010-06-30 Wellstat Biologics Corp DETECTION OF HER2 / NEU PROTEIN FROM UNISISIONED CIRCULATING CANCER CELLS AND TREATMENT
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
CA2911990C (en) 2007-09-10 2018-03-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20110306572A1 (en) 2007-09-24 2011-12-15 Tragara Pharmaceuticals, Inc COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
JP2011502571A (ja) 2007-11-05 2011-01-27 ピュアテック ベンチャーズ 医薬化合物を投与するための方法、キット、および組成物
CN101185633A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
US20110091524A1 (en) 2007-12-18 2011-04-21 Yan Wang Biomarkers for sensitivity to anti-igf1r therapy
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
EP2250498B1 (en) 2008-02-25 2012-10-31 Prometheus Laboratories Inc. Drug selection for breast cancer therapy using antibody-based arrays
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
JP2011515478A (ja) 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009126662A1 (en) 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
AU2009251437B2 (en) 2008-04-18 2014-10-30 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
DK2271658T3 (en) 2008-04-18 2017-02-06 Reata Pharmaceuticals Inc ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
LT2276493T (lt) 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
AU2009237578C1 (en) 2008-04-18 2014-12-04 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
EP4424375A2 (en) 2008-08-04 2024-09-04 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
WO2010045318A2 (en) 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
WO2010054051A1 (en) 2008-11-07 2010-05-14 Santaris Pharma A/S Erbb-3 (her3)-selective combination therapy
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
JP2012516895A (ja) 2009-02-04 2012-07-26 バイパー サイエンシズ，インコーポレイティド 成長因子阻害剤と組み合わせたｐａｒｐ阻害剤による肺がんの治療
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
PL3000467T3 (pl) 2009-04-06 2023-05-02 Wyeth Llc Schemat leczenia wykorzystujący neratynib dla raka sutka
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
EP2448563A2 (en) 2009-07-02 2012-05-09 Wyeth LLC 3-cyanoquinoline tablet formulations and uses thereof
KR20110007985A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR20110007984A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025269A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025267A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
US20110055838A1 (en) 2009-08-28 2011-03-03 Moyes William A Optimized thread scheduling via hardware performance monitoring
US20120244116A1 (en) 2009-10-01 2012-09-27 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia
EP4066821A1 (en) 2009-11-09 2022-10-05 Wyeth LLC Tablet formulations of neratinib maleate
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
PT2719708T (pt) 2009-11-13 2018-01-16 Daiichi Sankyo Europe Gmbh Material e métodos para tratamento ou prevenção de doenças associadas a her-3
WO2011069962A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
CA2783743C (en) 2009-12-11 2022-10-04 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

Also Published As

Publication number Publication date
ECSP088423A (es) 2008-06-30
US20120308560A1 (en) 2012-12-06
JP6232463B2 (ja) 2017-11-15
AU2006311877A1 (en) 2007-05-18
JP2014098040A (ja) 2014-05-29
US20070104721A1 (en) 2007-05-10
CN103110948A (zh) 2013-05-22
EP1942937A1 (en) 2008-07-16
RU2451524C2 (ru) 2012-05-27
JP5952679B2 (ja) 2016-07-13
JP2012214521A (ja) 2012-11-08
US20090297519A1 (en) 2009-12-03
JP6040303B2 (ja) 2016-12-07
JP2016128524A (ja) 2016-07-14
NO20081837L (no) 2008-07-30
CA2626326A1 (en) 2007-05-18
KR101354828B1 (ko) 2014-02-18
JP2018203783A (ja) 2018-12-27
RU2008115454A (ru) 2009-12-10
US20220354820A1 (en) 2022-11-10
EP3488866A1 (en) 2019-05-29
US20140050721A1 (en) 2014-02-20
BRPI0618042A2 (pt) 2011-08-16
JP6522056B2 (ja) 2019-05-29
WO2007056118A1 (en) 2007-05-18
JP2009514870A (ja) 2009-04-09
TW200803892A (en) 2008-01-16
CA2626326C (en) 2021-02-16
CR9901A (es) 2008-07-29
RU2012100913A (ru) 2013-07-20
JP2017171693A (ja) 2017-09-28
KR20080064156A (ko) 2008-07-08
PE20070763A1 (es) 2007-08-08
JP2016041767A (ja) 2016-03-31
IL190805A0 (en) 2008-11-03
US20230201155A1 (en) 2023-06-29
IL190805A (en) 2011-08-31
RU2632104C2 (ru) 2017-10-02
US10729672B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
AR057854A1 (es) Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
HRP20201882T1 (hr) SPOJEVI 7-FENILETILAMINO-4H-PIRIMIDO[4,5-d][1,3]OKSAZIN-2-ONA KAO INHIBITORI MUTANTNIH IDH1 I IDH2
RU2009113615A (ru) Ингибитор киназы
BRPI0716171B8 (pt) composto, composição farmacêutica e uso de um composto
JP2020502157A5 (es)
CY1121043T1 (el) Θεραπευτικες ενωσεις
JP2009514870A5 (es)
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
HRP20212021T1 (hr) 4-IMIDAZOPIRIDAZIN-1-iL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI KAO INHIBITORI BTK
NO20075427L (no) Ny farmasoytisk formulering inneholdende et biguanid og et tiazolidindionderivat
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2004000788A1 (es) Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
AR056786A1 (es) Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
AR086528A2 (es) Combinacion farmaceutica
RU2010128512A (ru) Гетероциклические ингибиторы мек и способы их применения
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
AR057835A1 (es) Derivados de 9- azabiciclo (3.3.1)nonano y composicion farmaceutica
WO2006077025A3 (en) Morpholines as 5ht2c agonists
JP2006508953A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure